Study participants were assessed at baseline, 6, 12, 18 and 24 months. They were examined for clinical signs of trachoma using 2.5x binocular loupes. On each occasion high resolution digital photographs were taken of the upper tarsal conjunctiva, for subsequent grading and comparison by a single ophthalmologist experienced in trachoma grading. Features were graded using the detailed WHO trachoma grading system with previously described modifications [6 (link),8 (link),11 ]. The tarsal conjunctival grading system is described in S1 Table [8 (link)]. Significant conjunctival inflammation was defined as the presence of papillary inflammation grades P2 or P3 of the detailed WHO Trachoma Grading System [11 ]. In both studies only one eye per person was included in the analysis for scarring progression and for the collection of conjunctival swab samples. In the Ethiopian study for individuals with bilateral trichiasis, the clinical trial study eye was randomly designated for inclusion as the outcome of epilation or surgery could be influenced by the laterality, although both eyes were treated. In the Tanzanian study the left eye was designated the study eye for all participants, for protocol simplicity.
On each occasion the ocular surface was anaesthetised with preservative-free proxymetacaine 0.5% eye drops (Minims, Chauvin Pharmaceuticals). Two conjunctival swab samples were collected from the upper tarsal conjunctival surface by making four horizontal passes across the conjunctival surface with a quarter turn between each pass (Dacron polyester-tipped swab: Hardwood Products Company). The first swab was collected for RNA isolation and placed directly into a tube containing 0.3ml of RNAlater (Life Technologies). The second swab was collected for a DNA primed C. trachomatis PCR and was placed in a dry tube. Samples were kept on ice packs until frozen later the same day at—20°C. Long-term storage was at -80°C. The Ethiopian samples were transferred to Tanzania on dry ice for analysis.
Free full text: Click here